You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
Mallinckrodt
McKinsey
McKesson

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for LY2623091

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for LY2623091?

LY2623091 is an investigational drug.

There have been 5 clinical trials for LY2623091. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2014.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Hypertension. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].

There is one US patent protecting this investigational drug and forty-one international patents.

Recent Clinical Trials for LY2623091
TitleSponsorPhase
A Study of LY2623091 in Healthy ParticipantsEli Lilly and CompanyPhase 1
A Study of How the Body Breaks Down and Eliminates LY2623091Eli Lilly and CompanyPhase 1
A Study of LY2623091 in Participants With High Blood PressureEli Lilly and CompanyPhase 2

See all LY2623091 clinical trials

Clinical Trial Summary for LY2623091

Top disease conditions for LY2623091
Top clinical trial sponsors for LY2623091

See all LY2623091 clinical trials

International Patents for LY2623091

Drugname Country Document Number Estimated Expiration Related US Patent
LY2623091 Argentina 069554 2027-12-19   Start Trial
LY2623091 Australia 2008343524 2027-12-19   Start Trial
LY2623091 Brazil PI0820805 2027-12-19   Start Trial
LY2623091 Canada 2710409 2027-12-19   Start Trial
LY2623091 Chile 2008003600 2027-12-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
Mallinckrodt
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.